Loading
A phase 1/2 trial of Capecitabine, Atezolizumab, Ipatasertib, Bevacizumab, Carboplatin and Eribulin in advanced solid tumours, run by Hoffmann-La Roche, now recruiting.
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer is a phase 1/2 interventional study registered as NCT03424005 by Hoffmann-La Roche, with 1132 participants planned, started 2018-03-30 and due to reach its primary completion in 2030-09-30. Interventions recorded: Capecitabine, Atezolizumab, Ipatasertib, SGN-LIV1A, Bevacizumab and Chemotherapy (Gemcitabine + Carboplatin or Eribulin).
Shares Flatiron Health (Roche), Atezolizumab, Bevacizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Flatiron Health (Roche), Atezolizumab, Bevacizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Eribulin, Gilead Sciences (incl. Kite), Capecitabine, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Ipatasertib, Flatiron Health (Roche), Atezolizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Eribulin, Capecitabine, Carboplatin and the tag pipeline.
Shares Eribulin, Capecitabine, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Eribulin, Capecitabine, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Bevacizumab, Carboplatin, Metastatic cancer (cancer that has spread) and the tag pipeline.